BioNeutra Global Corporation
BGA.V
TSX
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 8.35M | 8.98M | 9.45M | 10.34M | 11.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.35M | 8.98M | 9.45M | 10.34M | 11.82M |
| Cost of Revenue | 7.47M | 8.12M | 8.23M | 8.48M | 9.52M |
| Gross Profit | 887.00K | 860.00K | 1.22M | 1.86M | 2.31M |
| SG&A Expenses | 3.64M | 3.74M | 3.67M | 3.55M | 4.04M |
| Depreciation & Amortization | 192.50K | 180.50K | 164.80K | 152.90K | -150.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.42M | 12.16M | 12.06M | 12.17M | 13.32M |
| Operating Income | -3.07M | -3.17M | -2.61M | -1.83M | -1.49M |
| Income Before Tax | -3.49M | -3.44M | -2.99M | -2.21M | -1.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.49 | -3.44 | -2.99 | -2.21 | -1.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.49M | -3.44M | -2.99M | -2.21M | -1.84M |
| EBIT | -3.07M | -3.17M | -2.61M | -1.83M | -1.49M |
| EBITDA | -2.32M | -2.42M | -1.82M | -1.02M | -356.50K |
| EPS Basic | -0.07 | -0.07 | -0.06 | -0.05 | -0.04 |
| Normalized Basic EPS | -0.04 | -0.05 | -0.04 | -0.03 | -0.03 |
| EPS Diluted | -0.08 | -0.08 | -0.07 | -0.05 | -0.04 |
| Normalized Diluted EPS | -0.04 | -0.05 | -0.04 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 186.55M | 186.30M | 186.05M | 185.80M | 185.80M |
| Average Diluted Shares Outstanding | 186.55M | 186.30M | 186.05M | 185.80M | 185.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
